Key result
Universal pediatric plus reverse cascade screening for familial hypercholesterolemia is cost-effective at ~¥153,000 per QALY.
Why the study?
Familial hypercholesterolemia increases lifetime risk of ASCVD, making early identification and linkage to definitive diagnosis, treatment, family-based management, and life-long follow-up essential across varying international screening programs.
This narrative review highlights that integrating pediatric and cascade screening for familial hypercholesterolemia with coordinated healthcare delivery systems is essential to ensure early lipid-lowering therapy, life-long management, and long-term ASCVD prevention.
Answers are grounded in this paper and cite their sources.
May inform Japanese FH screening policy; leaves open prospective validation before broader adoption.
Familial hypercholesterolemia (FH) is a common autosomal dominant disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels from birth and an increased lifetime risk of atherosclerotic cardiovascular disease (ASCVD). Early identification and treatment are therefore essential to reduce cumulative LDL-C exposure. Several approaches to FH screening have been proposed, including cascade, reverse cascade, opportunistic, selective, and universal screening, each with distinct advantages, limitations, and implementation requirements. In particular, pediatric screening provides an opportunity for early diagnosis and treatment while also facilitating the identification of affected family members. Screening programs have been implemented differently across countries and regions according to healthcare systems and existing screening infrastructure, with regional universal screening programs also emerging in Japan.However, the value of FH screening extends beyond case detection. Individuals identified through screening should be linked to a definitive diagnosis, risk assessment, treatment, family-based management, and life-long follow-up. This review summarizes current FH screening strategies and their international implementation, with particular emphasis on pediatric detection, and discusses subsequent clinical management and future approaches to sustainable life-long care. Integrating effective screening with coordinated healthcare delivery systems is essential to translate early detection into long-term ASCVD prevention.
No takes yet. Share an insight, caveat, or question.
Inoue et al. (2026) conducted a review in Familial hypercholesterolemia. Familial hypercholesterolemia screening (universal, cascade, reverse cascade, opportunistic, selective) was evaluated. Combining universal pediatric screening at ages 9-10 with reverse cascade screening in Japan is cost-effective at ¥153,254 per QALY for lifelong familial hypercholesterolemia care.
Synapse has enriched 10 related papers. Consider them for comparative context: